<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03154047</url>
  </required_header>
  <id_info>
    <org_study_id>NEOD001-OLE251</org_study_id>
    <nct_id>NCT03154047</nct_id>
  </id_info>
  <brief_title>Study in Subjects With Light Chain (AL) Amyloidosis</brief_title>
  <official_title>A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prothena Biosciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prothena Biosciences Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in&#xD;
      subjects with AL amyloidosis who have completed Study NEOD001-201.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Global, multicenter, Phase 2b, open-label extension study of subjects with AL amyloidosis who&#xD;
      had a hematologic response to first-line treatment for their amyloidosis (e.g., chemotherapy,&#xD;
      autologous stem cell transplant [ASCT]) and completed Study NEOD001-201. Subjects in this&#xD;
      study may receive concomitant chemotherapy. Subject screening will occur during the 28 days&#xD;
      prior to the first administration of study drug, which may overlap with the last visit in&#xD;
      Study NEOD001-201. If all eligibility requirements are met, the subject will be enrolled and&#xD;
      Screening assessments will be completed. Study visits will occur every 28 days based on&#xD;
      scheduling from Month 1 Day 1. A ±5-day window is allowed for visits starting after Month 1.&#xD;
      Subjects who discontinue study drug before the End of Study Visit (EOS) should have an Early&#xD;
      Treatment Discontinuation Visit 30 (±5) days after their final administration of study drug.&#xD;
      Each subject's study participation may be up to 38 months or until the study is terminated,&#xD;
      whichever occurs first. The study consists of a Screening Phase (1 month), Treatment Phase&#xD;
      (36 months), and EOS Visit (30 [±5] days after the last dose).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    NEOD001 program terminated due to lack of clinical benefit&#xD;
  </why_stopped>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">May 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Each subject's study participation may have been up to 36 months or until the study was terminated</time_frame>
    <description>AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome, or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>AL Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label Study Drug NEOD001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEOD001</intervention_name>
    <description>humanized monoclonal antibody</description>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Completed the End of Study Visit in Study NEOD001-201&#xD;
&#xD;
          2. Adequate bone marrow reserve, hepatic and renal function, as demonstrated by:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1.0 × 109/L&#xD;
&#xD;
               -  Platelet count ≥75 × 109/L&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤2 × upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) ≤3 × ULN&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) ≤3 × ULN&#xD;
&#xD;
               -  Alkaline phosphatase (ALP) ≤5 × ULN (except for subjects with hepatomegaly and&#xD;
                  isozymes specific to liver, rather than bone)&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 as estimated by&#xD;
                  the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, or&#xD;
                  measured GFR ≥25 mL/min/1.73 m2&#xD;
&#xD;
          3. Systolic blood pressure 80-180 mmHg&#xD;
&#xD;
          4. Women of childbearing potential must have a negative pregnancy test during Screening&#xD;
             and must agree to use highly effective physician-approved contraception from Screening&#xD;
             to 90 days following the last study drug administration&#xD;
&#xD;
          5. Male subjects must be surgically sterile or must agree to use highly effective&#xD;
             physician-approved contraception from Screening to 90 days following the last study&#xD;
             drug administration&#xD;
&#xD;
          6. Ability to understand and willingness to sign an informed consent form prior to&#xD;
             initiation of any study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any new medical contraindication or clinically significant abnormality on physical,&#xD;
             neurological, laboratory, vital signs, or electrocardiographic (ECG) examination&#xD;
             (e.g., atrial fibrillation; with the exception of subjects for whom the ventricular&#xD;
             rate is controlled) that precludes continuation or initiation of treatment with&#xD;
             NEOD001 or participation in the study&#xD;
&#xD;
          2. Symptomatic orthostatic hypotension that in the medical judgment of the Investigator&#xD;
             would interfere with subject's ability to safely receive treatment or complete study&#xD;
             assessments&#xD;
&#xD;
          3. Myocardial infarction, uncontrolled angina, uncontrolled ventricular arrhythmias, or&#xD;
             ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit&#xD;
&#xD;
          4. Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area &lt;1.0 cm2)&#xD;
             or severe congenital heart disease&#xD;
&#xD;
          5. ECG evidence of acute ischemia or active conduction system abnormalities with the&#xD;
             exception of any of the following:&#xD;
&#xD;
               -  First degree atrioventricular (AV) block&#xD;
&#xD;
               -  Second degree AV block Type 1 (Mobitz Type 1/ Wenckebach type)&#xD;
&#xD;
               -  Right or left bundle branch block&#xD;
&#xD;
               -  Atrial fibrillation with a controlled ventricular rate (uncontrolled [i.e., &gt;110&#xD;
                  bpm] ventricular rate is not allowed [determined by an average of three beats in&#xD;
                  Lead II or 3 representative beats if Lead II is not representative of the overall&#xD;
                  ECG])&#xD;
&#xD;
          6. Has not recovered (i.e., equivalent to a Common Terminology Criteria for Adverse&#xD;
             Events [CTCAE] ≥Grade 2) from the clinically significant toxic effects of prior&#xD;
             anticancer therapy. Exception: subjects who have received treatment with a proteasome&#xD;
             inhibitor such as bortezomib may have CTCAE Grade 2 neuropathy.&#xD;
&#xD;
          7. Received any of the following within the specified time frame prior to the Month 1-Day&#xD;
             1 Visit:&#xD;
&#xD;
               -  Oral or IV antibiotics, antifungals, or antivirals within 1 week, with the&#xD;
                  exception of prophylactic oral agents. Note: In the event that a subject requires&#xD;
                  the chronic use of antivirals, Medical Monitor permission is required for entry&#xD;
                  into the study.&#xD;
&#xD;
               -  Hematopoietic growth factors, transfusions of blood or blood products within 1&#xD;
                  week&#xD;
&#xD;
               -  Chemotherapy, radiotherapy, HDAC inhibitors, or other plasma cell directed&#xD;
                  therapy within 2 weeks&#xD;
&#xD;
               -  ASCT within 4 weeks (i.e., ASCT is allowed if it occurred before enrollment in&#xD;
                  Study NEOD001-201 or after completion of Study NEOD001-201 if it was at least 4&#xD;
                  weeks before Month 1-Day 1 of this study)&#xD;
&#xD;
               -  Major surgery within 4 weeks (or within 2 weeks following consultation with and&#xD;
                  approval of Medical Monitor)&#xD;
&#xD;
               -  Planned organ transplant during the study&#xD;
&#xD;
               -  Any investigational agent, other than NEOD001, within 4 weeks&#xD;
&#xD;
               -  Any experimental imaging agent directed at amyloid within 2 weeks&#xD;
&#xD;
          8. Active malignancy with the exception of any of the following:&#xD;
&#xD;
               -  Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ&#xD;
                  cervical cancer&#xD;
&#xD;
               -  Adequately treated Stage I cancer from which the subject is currently in&#xD;
                  remission and has been in remission for ≥2 years&#xD;
&#xD;
               -  Low-risk prostate cancer with Gleason score &lt;7 and prostate-specific antigen &lt;10&#xD;
                  mg/mL&#xD;
&#xD;
               -  Any other cancer from which the subject has been disease-free for ≥2 years&#xD;
&#xD;
          9. History of Grade ≥3 infusion-related adverse events (AEs) or hypersensitivity to&#xD;
             NEOD001&#xD;
&#xD;
         10. History of severe allergy to any of the components of NEOD001 such as&#xD;
             histidine/L-Histidine, Trehalose, or Polysorbate 20&#xD;
&#xD;
         11. Currently known uncontrolled bacterial, viral, fungal, HIV, hepatitis B, or hepatitis&#xD;
             C infection&#xD;
&#xD;
         12. Women who are breastfeeding&#xD;
&#xD;
         13. Any condition which could interfere with, or the treatment for which might interfere&#xD;
             with, the conduct of the study or which would, in the opinion of the Investigator,&#xD;
             unacceptably increase the subject's risk by participating in the study&#xD;
&#xD;
         14. Unable or unwilling to adhere to the study-specified procedures and restrictions&#xD;
&#xD;
         15. Subject is under legal custodianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital - Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Health (Box Hill Hospital)</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren - CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Duisburg-Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center (HMC)</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <results_first_submitted>November 15, 2018</results_first_submitted>
  <results_first_submitted_qc>November 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2018</results_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03154047/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03154047/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NEOD001 24 mg/kg</title>
          <description>NEOD001, 24 mg/kg IV every 4 weeks for 36 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Number of Patients Dosed</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NEOD001 24 mg/kg</title>
          <description>NEOD001, 24 mg/kg IV every 4 weeks for 36 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" spread="8.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome, or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.</description>
        <time_frame>Each subject's study participation may have been up to 36 months or until the study was terminated</time_frame>
        <population>OLE Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>NEOD001 24 mg/kg</title>
            <description>NEOD001, 24 mg/kg IV every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome, or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.</description>
          <population>OLE Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Number Baseline Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (all causes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death Resulting from Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Initiation of study drug through study completion, up to 11 months</time_frame>
      <desc>AE that newly appears, increases in frequency, or worsens in severity following initiation of study drug and through the last study visit or up to 30 days after date of last dose, whichever is later.</desc>
      <group_list>
        <group group_id="E1">
          <title>NEOD001 24 mg/kg</title>
          <description>NEOD001, 24 mg/kg IV every 4 weeks for 36 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA19.0 Hierarchy</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal angiodysplasia haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA19.0 Hierarchy</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI, institution and the sponsor have agreed that the PI and institution may publish or disclose study results from their site after the earlier of (a) publication of the complete multicenter study results or (b) 18 months after database lock for the multicenter study. The sponsor has at least 45 days to review a proposed publication and may request deletion of confidential information and up to 60 days additional delay to obtain patent protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wendy Curlin</name_or_title>
      <organization>Prothena Biosciences</organization>
      <phone>650 837 8550</phone>
      <email>clinicaltrials@prothena.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

